TABLE OF CONTENTS
Executive Summary 7
Industry analysis 7
Industry definition 7
Research highlights 7
Top 10 companies landscape 8
Market Value 9
Market Forecast 10
Market Segmentation: Product 11
Market Segmentation: Geographic 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
Top 10 Companies Landscape 19
Overview 19
Revenue analysis 23
Financial performance analysis 25
Company Reports 30
Pfizer 30
F. Hoffmann-La Roche 36
Novartis 42
GlaxoSmithKline 49
Sanofi-Aventis 56
AstraZeneca 64
Abbott Laboratories 74
Merck & Co. 80
Eli Lilly and Company 86
Bristol-Myers Squibb Company 94
Five-Year Financial Information 99
Pfizer 99
F. Hoffman-La Roche 102
Novartis 105
GlaxoSmithKline 108
Sanofi-Aventis 111
AstraZeneca 114
Abbott Laboratories 117
Merck & Co. 120
Eli Lilly and Company 123
Bristol-Myers Squibb Company 126
Appendix 129
FIGURES
Figure 1: Global pharmaceuticals market ($ billion), 2005–09 9
Figure 2: Global pharmaceuticals market forecast ($ billion), 2009–14 10
Figure 3: Global pharmaceuticals market segmentation: product (% share), 2009 11
Figure 4: Global pharmaceuticals market segmentation: geography (% share), 2009 12
Figure 5: Forces driving competition in the global pharmaceuticals market, 2009 13
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2009 14
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2009 15
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2009 16
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2009 17
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2009 18
Figure 11: Revenues of global top 10 pharmaceutical companies ($m), FY2009 20
Figure 12: Revenue growth of the global top 10 pharmaceutical companies, FY2007–09 24
Figure 13: Operating performance analysis, FY2009 26
Figure 14: Net profit analysis, FY2009 27
TABLES
Table 1: Global pharmaceutical market ($ billion), 2005–09 9
Table 2: Global pharmaceuticals market forecast ($ billion), 2009–14 10
Table 3: Global pharmaceuticals market segmentation: product (% share), 2009 11
Table 4: Global pharmaceuticals market segmentation: geography (% share), 2009 12
Table 5: Revenues and sales of global top 10 pharmaceutical companies ($m), FY2009 20
Table 6: Revenue growth of global top 10 pharmaceutical companies, FY2007–09 23
Table 7: Key financials of the global top 10 pharmaceutical companies, FY2009 25
Table 8: Key industry-specific ratios, FY2009 28
Table 9: Pfizer: financial and operational highlights, 2005–09 ($m) 99
Table 10: Pfizer: key industry-specific ratios, 2005–09 101
Table 11: F. Hoffman-La Roche: financial and operational highlights, 2005–09 ($m) 102
Table 12: F. Hoffman-La Roche: key industry-specific ratios, 2005–09 104
Table 13: Novartis: financial and operational highlights, 2005–09 ($m) 105
Table 14: Novartis: key industry-specific ratios, 2005–09 107
Table 15: GlaxoSmithKline: financial and operational highlights, 2005–09 ($m) 108
Table 16: GlaxoSmithKline: key industry-specific ratios, 2005–09 110
Table 17: Sanofi-Aventis: financial and operational highlights, 2005–09 ($m) 111
Table 18: Sanofi-Aventis: key industry-specific ratios, 2005–09 113
Table 19: AstraZeneca: financial and operational highlights, 2005–09 ($m) 114
Table 20: AstraZeneca: key industry-specific ratios, 2005–09 116
Table 21: Abbott Laboratories: financial and operational highlights, 2005–09 ($m) 117
Table 22: Abbott Laboratories: key industry-specific ratios, 2005–09 119
Table 23: Merck & Co.: financial and operational highlights, 2005–09 ($m) 120
Table 24: Merck & Co.: key industry-specific ratios, 2005–09 122
Table 25: Eli Lilly and Company: financial and operational highlights, 2005–09 ($m) 123
Table 26: Eli Lilly and Company: key industry-specific ratios, 2005–09 125
Table 27: Bristol-Myers Squibb Company: financial and operational highlights, 2005–09 ($m) 126
Table 28: Bristol-Myers Squibb Company: key industry-specific ratios, 2005–09 128
[Inhaltsverzeichnis ausblenden]